Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totalling more than 3,500 GPUs, following an expansion of its global AI infrastructure. 

The company has deployed a large-scale AI factory powered by a full stack of the latest-generation NVIDIA accelerated computing and AI, marking the next phase of a NVIDIA collaboration that started in 2023. 

Featuring 2,176 high-performance GPUs on premises across the United States and Europe, the infrastructure is designed to accelerate the development of diagnostics solutions and therapeutics.  

“In healthcare, time is the most critical variable; every day saved means a life-changing medicine or diagnostic reaches a patient sooner,” said Wafaa Mamilli, Roche’s Chief Digital and Technology Officer. “Our AI factory combines world-class computing power with Roche’s scientific expertise to embed AI across the entire value chain — from discovery to development, manufacturing and commercialisation — transforming how we deliver the next generation of medicines and diagnostics solutions.” 

In R&D, the NVIDIA BioNeMo platform enhances Roche’s Lab-in-the-Loop, where biological and chemistry experiments are connected with Roche’s AI models. This helps scientists test hypotheses at scale, accelerate progress, and make discoveries that were not possible otherwise. 

“Our expanded collaboration with NVIDIA and the launch of this AI factory further strengthens our leadership in AI-driven drug discovery and development,” said Aviv Regev, Executive Vice President and Head of Genentech Research and Early Development (gRED). “By providing the massive computational power needed to continue to scale our Lab-in-the-Loop strategy — a space we have pioneered for over five years — our scientists can build more sophisticated predictive frontier models and further shorten the path from biological insight to life-saving medicine.” 

The post Roche leads AI drug discovery with new NVIDIA deal appeared first on Drug Discovery World (DDW).